High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients.
J. Infect. 2020 Sep 1; 81 (3): 420-426.
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured...
Trials. 2020 Jun 8; 21 (1): 498.
Comparative Global Epidemiological Investigation of SARS-CoV-2 and SARS-CoV Diseases Using Meta-MUMS Tool Through Incidence, Mortality, and Recovery Rates.
Arch. Med. Res. 2020 Jul 1; 51 (5): 458-463.